Sign in
Taking people in United StatesPhase 1

Testing Treatments to Prevent Diabetes, Obesity and Heart Risk in Hispanic Adults

Tests several drugs against placebo in adults with prediabetes and obesity.

Key facts

Who runs it
The University of Texas Health Science Center at San Antonio
Where
San Antonio, United StatesSee the site
Trial code
Registry title
Prevention of Progression of Prediabetes, Obesity and CV Risk
Status
Recruiting
Phase
Phase 1
People taking part
64 people, planned
Started
11 Sept 2024
Expected to end
Jul 2027
Type of study
Interventional, 4 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Placebo
  • Rybelsus Tablet
  • Jardiance 25Mg Tablet
  • Metformin
  • Actos
Record updated
12 November 2025

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for Hispanic adults with prediabetes and a higher body weight. It tests treatments to bring blood sugar back to normal, help weight loss and lower heart risk.

Age
18 years or older.
Sex
All sexes can join. Women must not be pregnant or breast-feeding.
Disease stage
Prediabetes diagnosed in the last 6 months, with HbA1c 5.7-6.4% (39–46 mmol/mol) and BMI 25-40 kg/m2. Blood pressure under 160/100. eGFR of 30 ml/min•1.73m2 or more.
Earlier treatment
Body weight stable (±5 pounds (2 kg)) over the last 3 months. Oral diuretics, if used, stable for at least 1 week before randomization. Cannot be on one of the selected therapies now.
Biomarker or test result
HbA1c 5.7-6.4% (39–46 mmol/mol).

Main reasons for not taking part

  • Type 2 diabetes
  • Pregnancy, breast-feeding, or women of childbearing age unwilling to use birth control
  • Heart attack, bypass surgery or other major heart event in the past 60 days
  • Heart transplant, implanted left ventricular assist device, or heart failure needing intravenous treatment
  • Cancer diagnosis in the last 5 years, or severe claustrophobia or any reason MRI is not safe (metal implants, pacemaker)

The registry criteria, word for word

Show all 29 criteriaShow less

Who can take part

  • Patients will have an established diagnosis of pre-Diabetes Mellitus (DM) before the screening visit, documented by an acceptable modality in the last 6 months
  • Age ≥ 18 years old
  • Body Mass Index (BMI)=25-40 kg/m2
  • Glycated Hemoglobin (HbA1c) = 5.7-6.4%
  • Blood Pressure (BP) <160/100
  • Estimated Glomerular Filtration Rate (eGFR) ≥30 ml/min•1.73m2
  • Body weight must be stable (±5 pounds) over the last 3 months
  • Oral diuretics, if prescribed to the patient according to local guidelines and discretion of the investigator, should be stable for at least 1 week prior to randomization
  • Hispanic ethic group
  • Willing to adhere to medication regimen for up to 6 months
  • Male or female, if female, met these criteria:; Not pregnant or breast-feeding; Negative pregnancy test result at visit 1 (screening); During the entire study, women of childbearing potential (WOCBP) including peri-menopausal women who have a menstrual period within 1 year must practice appropriate, and effective birth control, either implants or pills, or a vasectomized partner prior to receiving the first dose of study medication
  • Does not suffer from severe claustrophobia
  • No contraindication for Magnetic Resonance Imaging (MRI) (metal plates, screws, shrapnel, pins, or cardiac pacemaker)

Who cannot take part

  • Patients currently on one of the selected therapies
  • Current drug or alcohol use or dependence that, in the opinion of the site investigator, would interfere with adherence to study requirements
  • Acute decompensated heart failure requiring intravenous diuretics, vasodilators, inotropic agents, or mechanical support within 1 week of screening and during the screening period prior to randomization
  • Implanted cardioverter defibrillator within 3 months prior to screening
  • Extended diagnoses with Type 2 Diabetes
  • Known allergy/sensitivity to study drugs or their ingredients
  • Major organ or metabolic diseases, or physical limitations that will not allow the subject to complete the study
  • Myocardial infraction, coronary artery bypass graft surgery, or other major cardiovascular event in the past 60 days
  • Heart transplant recipient or listed for a heart transplant
  • Any severe (obstructive or regurgitant) valvular heart disease, expected to lead to surgery during the trial period
  • Cardiac resynchronization therapy
  • Pregnancy, lactation, women of childbearing age (WOCBA) unwilling to use contraception
  • Major oncologic diagnosis in the last 5 years
  • Inability or unwillingness of individual or legal guardian/representative to give written informed consent
  • Currently implanted left ventricular assist device
  • Cardiomyopathy based on infiltrative or cumulative hypertrophic obstructive cardiomyopathy or known pericardial constriction

Where in United States

  • University of Texas Health Science Center at San AntonioSan Antonio, United StatesContact: Carolina Solis-Herrera, MDTaking people

About the trial

What the trial wants to find out

The investigators are studying how to help people with prediabetes (Pre-DM) and obesity. The goal is to use new and affordable treatments to bring blood sugar levels back to normal and help participants to lose weight. The investigators also want to reduce participants risk of heart problems. The study team will look at how these treatments affect metabolism and other body functions to help find new ways to treat diabetes and obesity in the future.

The 4 groups in the trial

  • PlaceboPlacebo, for comparison

    Randomization will occur 1:1:1:1 to this placebo group

  • SGLT2 inhibitor GroupTreatment being tested

    Randomization will occur 1:1:1:1 to this SGLT2 inhibitor group

    Treatment: Jardiance 25Mg Tablet

  • GLP-1 Receptor Agonist GroupTreatment being tested

    Randomization will occur 1:1:1:1 to this GLP-1 receptor agonist group

    Treatment: Rybelsus Tablet

  • Metformin with SGLT2 Inhibitor GroupTreatment being tested

    Randomization will occur 1:1:1:1 to this metformin plus SGLT2 inhibitor group

    Treatment: Metformin and Actos

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Pioneering and Affordable Strategies to Prevent Progression of Prediabetes, Obesity and CV Risk in Hispanics
Plain-language title
Testing Treatments to Prevent Diabetes, Obesity and Heart Risk in Hispanic AdultsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
12 November 2025